GLP-1 Frenzy Continues: Eli Lilly Hits Record High, Q2 Expected to Shine, JPMorgan Targets $1,400, Multiple Brokers Raise Price Targets
NQ Score
91/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Eli Lilly (LLY-US) stock surged to a new all-time high on July 8, driven by JPMorgan's aggressive price target hike, strong Wall Street sentiment, and robust growth momentum in its GLP-1 drug portfolio, fueling investor confidence.
AI Analysis
Frequently Asked Questions
- Q: What are Eli Lilly's GLP-1 drugs?
- A: GLP-1 drugs treat diabetes and obesity. Key products include Mounjaro and Zepbound.
- Q: Why is Eli Lilly's stock rising?
- A: Strong demand for Mounjaro and Zepbound, plus price target hikes from major banks.
- Q: What next-gen GLP-1 drugs is Lilly developing?
- A: Oral orforglipron (Foundayo) and triple agonist retatrutide are in development.
- Q: What is Lilly's Q2 2024 forecast?
- A: Revenue of $20.7B and EPS of $8.85, above market expectations.
- Q: What is the GLP-1 Bridge Program?
- A: A U.S. program capping out-of-pocket costs at $50/month for Zepbound and Foundayo.